{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:21Z","timestamp":1793598201842,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016286","name":"Urmia University of Medical Sciences","doi-asserted-by":"publisher","award":["19724"],"award-info":[{"award-number":["19724"]}],"id":[{"id":"10.13039\/501100016286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinre.2023.102279","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T21:58:17Z","timestamp":1703800697000},"page":"102279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"48","author":[{"given":"Laya","family":"Hooshmand Gharabagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shargh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mohammad Hosseini Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-0248","authenticated-orcid":false,"given":"Ayda","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2023.102279_bib0001","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","article-title":"Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontl Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2023.102279_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2023.102279_bib0003","series-title":"The lancet gastroenterology & hepatology","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","author":"Riazi","year":"2022"},{"issue":"1","key":"10.1016\/j.clinre.2023.102279_bib0004","first-page":"6","article-title":"Epidemiology and risk factor of non-alcoholic fatty liver diseases in Iran and worldwide: a literature review","volume":"26","author":"Hormati","year":"2021","journal-title":"GOVARESH"},{"issue":"16","key":"10.1016\/j.clinre.2023.102279_bib0005","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.282.16.1519","article-title":"The spread of the obesity epidemic in the United States, 1991-1998","volume":"282","author":"Mokdad","year":"1999","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.clinre.2023.102279_bib0006","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.106.613828","article-title":"Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study","volume":"113","author":"Fox","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinre.2023.102279_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","article-title":"Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches","volume":"28","author":"Schuppan","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/antiox10020270","article-title":"Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review","volume":"10","author":"Rinaldi","year":"2021","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.clinre.2023.102279_bib0009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102279_bib0010","doi-asserted-by":"crossref","unstructured":"Hormati A., Khanyabi A., Ahmadpour S., Alemi F., Sarkeshikian S.S., Afifian M., et\u00a0al. Outcome of phlebotomy on improvement of liver enzymes and steatosis in non-alcoholic fatty liver disease: a randomized, controlled trial. 2022.","DOI":"10.30699\/jambs.30.143.493"},{"issue":"3","key":"10.1016\/j.clinre.2023.102279_bib0011","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/dme.13565","volume":"35","author":"Sberna","year":"2018","journal-title":"Diabetic Med"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"9","author":"EAftSoT","year":"2016","journal-title":"Obes Facts"},{"issue":"1","key":"10.1016\/j.clinre.2023.102279_bib0013","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2023.102279_bib0014","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.clinre.2023.102279_bib0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinre.2023.102279_bib0016","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.3390\/biomedicines10123294","article-title":"New Insights into the use of Empagliflozin\u2014a comprehensive review","volume":"10","author":"Forycka","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinre.2023.102279_bib0017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0018","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/biomedicines11020322","article-title":"Effects of a combination of Empagliflozin plus metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study","volume":"11","author":"Caturano","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinre.2023.102279_bib0019","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinre.2023.102279_bib0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2471\/BLT.08.050955","article-title":"The declaration of Helsinki and public health","volume":"86","author":"Williams","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"6","key":"10.1016\/j.clinre.2023.102279_bib0021","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.clinre.2023.102279_bib0022","first-page":"51","article-title":"New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome","volume":"4","author":"Bredy","year":"2018","journal-title":"Eur Heart J-Qual Care Clin Outcomes"},{"issue":"7","key":"10.1016\/j.clinre.2023.102279_bib0023","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.12557","article-title":"Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease","volume":"29","author":"Chan","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102279_bib0024","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3389\/fendo.2021.739875","article-title":"Validation of Controlled attenuation parameter measured by FibroScan as a novel surrogate marker for the evaluation of metabolic derangement","volume":"12","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement_1","key":"10.1016\/j.clinre.2023.102279_bib0025","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2023.102279_bib0026","article-title":"Real-world clinical experience on the usage of high-dose Metformin (1500-2500mg\/day) in type 2 diabetes management","volume":"14","author":"Das","year":"2021","journal-title":"Clin Med Insights: Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.fertnstert.2006.11.133","article-title":"Comparison of two doses of metformin (2.5 and 1.5g\/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference","volume":"88","author":"Bruno","year":"2007","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0028","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.clinre.2023.102279_bib0029","series-title":"Applied multiple regression\/correlation analysis for the behavioral sciences","author":"Cohen","year":"2013"},{"issue":"8","key":"10.1016\/j.clinre.2023.102279_bib0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1756283X17715198","article-title":"Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals","volume":"10","author":"Pons","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.clinre.2023.102279_bib0031","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions","volume":"49","author":"Lonardo","year":"2017","journal-title":"Digest Liver Dis"},{"issue":"30","key":"10.1016\/j.clinre.2023.102279_bib0032","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.clinre.2023.102279_bib0033","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes, Obes Metab"},{"issue":"4","key":"10.1016\/j.clinre.2023.102279_bib0034","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3748\/wjg.v21.i4.1158","article-title":"Factors associated with significant liver fibrosis assessed using transient elastography in general population","volume":"21","author":"You","year":"2015","journal-title":"World J Gastroenterol: WJG"},{"issue":"8","key":"10.1016\/j.clinre.2023.102279_bib0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.clinre.2023.102279_bib0036","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacl.2015.12.026","article-title":"Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol","volume":"10","author":"Wu","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinre.2023.102279_bib0037","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1007\/s10620-009-1075-y","article-title":"The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk","volume":"55","author":"Alkhouri","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2023.102279_bib0038","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:24:58Z","timestamp":1778840698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740123002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2210740123002048"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102279","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102279"}}